Inhibitory effect of roburic acid in combination with docetaxel on human prostate cancer cells

• Main Authors: Xiao Wang (Author), Xu Xuetao (Author), Mengshuo Wu (Author), Panpan Wu (Author), Zhaojun Sheng (Author), Wenfeng Liu (Author), Yan-Yan Ma (Author), Den-Gao Zhao (Author), Kun Zhang (Author), Dongli Li (Author), Xi Zheng (Author), Susan Goodin (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Roburic acid (ROB) is a naturally occurred tetracyclic triterpenoid, and the anticancer activity of this compound has not been reported. Docetaxel (DOC) is the first-line chemotherapeutic agent for advanced stage prostate cancer but toxic side effects and drug resistance limit its clinical success....